Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a women’s oncology company developing small molecule and
immunotherapy treatments for breast and gynecological
cancers, today announced that five abstracts have been
selected for poster or symposium presentations at the American
Association for Cancer Research (AACR) Annual Meeting 2022, taking
place April 8-13, 2022, at the Ernest N. Morial Convention Center
in New Orleans, LA.
“Context is committed to advancing new therapeutics for female
cancers and we are proud to have our compounds showcased at the
upcoming AACR Annual Meeting,” said Martin Lehr, CEO of Context
Therapeutics. “We look forward to the presentations from
investigators on lead product candidate onapristone extended
release (ONA-XR), a potent, specific progesterone receptor (PR)
antagonist being evaluated for PR+ breast, ovarian and endometrial
cancer, and our preclinical anti-claudin 6 (CLDN6) bispecific
monoclonal antibody (BsMAb) for gynecologic cancer therapy.”
Details of the presentations are as follows:
Title: Atomic-level specificity of Claudin 6 monoclonal
antibodies isolated for treating solid tumorsSession Category:
Experimental and Molecular TherapeuticsSession Title: Antibodies
and Immune TherapiesAbstract Number: 318Presenter: Joseph Rucker,
Ph.D., Integral MolecularDate and Time: April 10, 2022, 1:30 - 5:00
p.m.
Title: Targeting progesterone receptor (PR) with the
antiprogestin onapristone in patient-derived xenograft (PDX) models
of estrogen receptor positive (ER+), PR positive (PR+) bone
metastasis of breast cancerSession Category: MinisymposiumSession
Title: New Approaches to Targeting Hormone Dependent
CancersAbstract Number: 649Presenter: Elisabetta Marangoni, Ph.D.,
Institut CurieDate and Time: April 10, 2022, 3:00 - 5:00 p.m.
Title: Progesterone promotes immunomodulation and tumor
development in the murine mammary glandSession Category:
ImmunologySession Title: Molecular Signaling and Metabolic and
Epigenetic Regulation in Adaptive Tumor ImmunityAbstract Number:
1351Presenter: Lauryn Werner, M.D., Ph.D. Candidate, University of
KansasDate and Time: April 11, 2022, 9:00 a.m. - 12:30 p.m.
Title: Development of claudin 6 bispecific antibodies for
treatment of ovarian cancerSession Category: ImmunologySession
Title: Therapeutic Antibodies 2Abstract Number: 2892Presenter:
Joseph Rucker, Ph.D., Integral MolecularDate and Time: April 12,
2022, 9:00 a.m. - 12:30 p.m.
Title: PR/STAT3 nuclear transcriptional complexes mediate
aurora-A kinase-induced stemness plasticity in ER+ breast
cancerSession Category: Tumor BiologySession Title: Stem Cells and
Regulatory Pathways in CancerAbstract Number: 3163Presenter:
Antonio D’Assoro, M.D., Ph.D., Mayo ClinicDate and Time: April 12,
2022, 1:30 - 5:00 p.m.
For more information and to view the abstracts, visit the AACR
Annual Meeting website.
On Wednesday, April 13, 2022, at 11 a.m. ET, Context will host a
webinar with its management team and AACR presenters, to discuss
the results from these presentations and provide updates on the
ONA-XR clinical program. Following the formal presentation, the
Context team, along with AACR presenters, will be available for
questions. To register for the webinar, please click here.
Additionally, a replay of the webinar will be available on the
Events page of the Investor Relations section of Context’s
website, www.contexttherapeutics.com, for approximately 30
days after the webinar.
About Context
Therapeutics®Context Therapeutics Inc.
(Nasdaq: CNTX), is a women’s oncology company developing small
molecule and immunotherapy treatments to transform care for breast
and gynecological cancers. The Company’s robust clinical program
for lead candidate onapristone extended release (ONA-XR) comprises
three Phase 2 clinical trials and one Phase 1b/2 clinical trial in
hormone-driven breast, ovarian, and endometrial cancer. ONA-XR is a
novel, first-in-class small molecule under development as a potent
and specific antagonist of the progesterone receptor, a key
unchecked mechanism in hormone-driven women’s cancers. Context is
headquartered in Philadelphia, PA. For more information, visit
www.contexttherapeutics.com.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as "may," "will," "expect," "anticipate," "plan," "intend," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the results of our clinical trials, (ii)
the potential benefits of the product candidates, (iii) the
likelihood data will support future development, (iv) the ability
of the Company, its employees and certain AACR presenters to
participate in and present at conferences and webinars, and (v) the
likelihood of obtaining regulatory approval of our product
candidates. Forward-looking statements in this release involve
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Other factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in our filings with
the U.S. Securities and Exchange Commission, including the
section titled “Risk Factors” contained therein. Except as
otherwise required by law, we disclaim any intention or obligation
to update or revise any forward-looking statements, which speak
only as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
Media Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Laine YonkerEdison
Grouplyonker@edisongroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Oct 2023 to Oct 2024